Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials

Ophthalmology

Volumn 121, Issue 5, 2014, Pages 1059-1066

  Thach, Allen B ^a   Yau, Linda ^b   Hoang, Carol ^b   Tuomi, Lisa ^b  

^a Retina Consultants of Nevada   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADOLESCENT; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL FOVEAL THICKNESS; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CHILD; CONTROLLED STUDY; HUMAN; IMMUNOTHERAPY; INFANT; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); NEWBORN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA FOVEA; RETINA MACULA EDEMA; RETROSPECTIVE STUDY; SHAM PROCEDURE; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETREATMENT; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84899973310     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.11.022     Document Type: Article

References (23)

1. P.A. Campochiaro Anti-vascular endothelial growth factor treatment for retinal vein occlusions Ophthalmologica 227 suppl 2012 30 35
2. R. Klein, S.E. Moss, S.M. Meuer, and B.E. Klein The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study Arch Ophthalmol 126 2008 513 518
3. S.S. Hayreh Neovascular glaucoma Prog Retin Eye Res 26 2007 470 485
4. P. Mitchell, W. Smith, and A. Chang Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study Arch Ophthalmol 114 1996 1243 1247
5. D.M. Brown, P.A. Campochiaro, and R.P. Singh et al. CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 2010 1124 1133
6. P.A. Campochiaro, J.S. Heier, and L. Feiner et al. BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 2010 1102 1112
7. D.M. Brown, P.A. Campochiaro, and R.B. Bhisitkul et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study Ophthalmology 118 2011 1594 1602
8. P.A. Campochiaro, D.M. Brown, and C.C. Awh et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study Ophthalmology 118 2011 2041 2049
9. I.J. Suner, G.T. Kokame, and E. Yu et al. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials Invest Ophthalmol Vis Sci 50 2009 3629 3635
10. R.L. McIntosh, S.L. Rogers, and L. Lim et al. Natural history of central retinal vein occlusion: an evidence-based systematic review Ophthalmology 117 2010 1113 1123
11. S.L. Rogers, R.L. McIntosh, and L. Lim et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review Ophthalmology 117 2010 1094 1101
12. P.G. Steinkuller Legal Vision requirements for drivers in the United States Virtual Mentor 12 2010 938 940
13. N.M. Bressler, T.S. Chang, and R. Varma et al. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab Ophthalmology 120 2013 160 168
14. J.H. Lim, S.S. Wickremasinghe, and J. Xie et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration Am J Ophthalmol 153 2012 678 686
15. P.S. Muether, R. Hoerster, and M.M. Hermann et al. Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 251 2013 453 458
16. P.A. Keane, S. Liakopoulos, and K.T. Chang et al. Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration Ophthalmology 115 2008 2206 2214
17. A. Salinas-Alaman, A. Garcia-Layana, and M.J. Maldonado et al. Using optical coherence tomography to monitor photodynamic therapy in age related macular degeneration Am J Ophthalmol 140 2005 23 28
18. D.M. Brown, L. Tuomi, and H. Shapiro PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration Retina 33 2013 23 34
19. S. Nunes, I. Pereira, and A. Santos et al. Central retinal thickness measured with HD-OCT shows a weak correlation with visual acuity in eyes with CSME Br J Ophthalmol 94 2010 1201 1204
20. Diabetic Retinopathy Clinical Research Network Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema Ophthalmology 114 2007 525 536
21. A. Catier, R. Tadayoni, and M. Paques et al. Characterization of macular edema from various etiologies by optical coherence tomography Am J Ophthalmol 140 2005 200 206
22. A.E. Hoeh, M. Ruppenstein, T. Ach, and S. Dithmar OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion Graefes Arch Clin Exp Ophthalmol 248 2010 1567 1572
23. V. Martinet, B. Guigui, and A. Glacet-Bernard et al. Macular edema in central retinal vein occlusion: correlation between optical coherence tomography, angiography and visual acuity Int Ophthalmol 32 2012 369 377